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Abstract
Acute pancreatitis (AP) is a common disease, which 
usually exists in its mild form. However, in a fifth of 
cases, the disease is severe, with local pancreatic 
complications or systemic organ dysfunction or both. 
Because the development of organ failure is the major 
cause of death in AP, early identification of patients 
likely to develop organ failure is important. AP is initi-
ated by intracellular activation of pancreatic proen-
zymes and autodigestion of the pancreas. Destruction 
of the pancreatic parenchyma first induces an inflam-
matory reaction locally, but may lead to overwhelming 
systemic production of inflammatory mediators and 
early organ failure. Concomitantly, anti-inflammatory 
cytokines and specific cytokine inhibitors are produced. 
This anti-inflammatory reaction may overcompensate 
and inhibit the immune response, rendering the host 
at risk of systemic infection. At present, there is no 
specific treatment for AP. Increased understanding of 
the pathogenesis of systemic inflammation and de-
velopment of organ dysfunction may provide us with 
drugs to ameliorate physiological disturbances.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Acute pancreatitis (AP) is a common disease though its 
incidence varies considerably in different countries from 
5 to more than 100 per 100 000 inhabitants/year[1-5]. AP 
is a disease with wide clinical variation. Most of  the pa-
tients suffer from mild disease but in about 20% of  the 
cases the patient develops a severe form of  the disease, 
with a mortality of  7%-15%[1,6,7]. The major cause of  
death is organ failure which complicates severe AP in 
20%-80% of  the cases[8,9]. 
AP has many distinct etiologies, though approximately 
80% of  all cases are caused by either gallstones or alco-
hol[10]. The frequency of  different etiologies varies mark-
edly in different countries. In Finland, alcohol is the caus-
ative factor in about 70% of  the cases and the incidence 
of  AP correlates with the rate of  alcohol consumption[11].
Prognosis of  severe AP has improved mainly be-
cause of  efficacious conservative treatment in intensive 
care units. Also the correct timing of  surgery is impor-
tant but is indicated only for infected organized pancre-
atic necrosis when percutaneous drainage techniques are 
ineffective[12]. In recent years, many minimally invasive 
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techniques, for example endoscopic and laparoscopic 
approaches, have been introduced to avoid the need for 
open necrosectomy[13]. However, in severe AP the inci-
dence of  intra-abdominal hypertension is 60%-80% and 
in some cases necessitates surgical decompression in the 
early phase of  the disease[14]. The use of  antimicrobial 
drug therapy does not protect against infected necrosis 
or reduce mortality in severe AP[15]. A factor which may 
affect the outcome is early endoscopic retrograde chol-
angiopancreatography (ERCP) in biliary AP with biliary 
obstruction[16]. Thus, despite extensive research during 
the recent decades, no mode of  treatment has been de-
veloped that could dramatically improve the outcome of  
severe AP. 
INFLAMMATORY RESPONSE IS SIMILAR 
IN AP AND SEPSIS
Previously, AP was considered to be a disease of  the 
pancreas. Nowadays, however, there is strong evidence 
for systemic effects of  the disease. The mechanisms of  
systemic inflammation resulting in organ failures are 
much alike in severe AP and in, for example, severe burn 
injury, multitrauma or sepsis[17] (Figure 1). Thus, a con-
siderable amount of  research data gained, for example, 
in sepsis studies could be applicable also in severe AP.
The initial phase of  AP involves triggering events 
that lead to premature activation of  pancreatic proteases 
as a result of  intracellular co-localization of  the digestive 
and lysosomal enzymes. This leads to disruption of  the 
acinar cells[18-20]. Then, activated enzymes escape into the 
interstitium of  the pancreas and cause pancreatic autodi-
gestion[21,22]. Furthermore, pancreatic damage is followed 
by activation of  local inflammatory cells and various 
inflammatory mediators (cytokines) (Figure 1). Localized 
inflammation is the body’s initial physiologic protective 
response, which is generally strictly controlled at the site 
of  injury. Loss of  the local control results in excessive 
uncontrolled activation of  inflammatory cells and media-
tors. This response is defined as systemic inflammatory 
response syndrome[23]. Proinflammatory cytokines, tu-
mor necrosis factor-α (TNF-α) and interleukin-1β (IL-
1β) are released via portal vein and lymph fluid drainage 
to the circulation[24]. In addition, the production of  cyto-
kines enhances proinflammatory signals. IL-6 stimulates 
the synthesis of  acute phase proteins (i.e. C-reactive pro-
tein and procalcitonin) in the liver[25]. Proinflammatory 
cytokines activate the vascular endothelium in the whole 
body, which leads to enhanced leakage of  the capillary 
veins and triggers migration of  leukocytes into tissues. 
promoting activation of  coagulation cascades. Circulat-
ing neutrophils and monocytes become activated, as evi-
denced by the increased expression of  adhesion mole-
cules (e.g. CD11b), and release their proteolytic enzymes 
and oxygen radicals, which damage vascular endothelial 
cells and organ parenchymal cells[26]. Enhanced amounts 
of  tissue fluid together with impaired microcirculation 
lead to lack of  oxygen, which results in dysfunction of  
vital organs and, ultimately, in organ failure[27,28]. While 
lungs and kidneys have a wide capillary bed, they are es-
pecially susceptible to phlogistic mediators inducing end 
organ injury.
ANTI-INFLAMMATORY RESPONSE
Systemic inflammation in AP is concomitantly associ-
ated with rapidly-strengthening compensatory anti-
inflammatory response syndrome (CARS)[29,30]. An anti-
inflammatory response may be sufficient to control the 
systemic inflammatory reaction, a sign of  good prognosis. 
However, CARS may be excessive leading to immune 
deficiency or suppression, which renders the host suscep-
tible to secondary infections. In AP, an increased number 
of  infections has been observed in a later stage of  the 
disease[31], i.e. at the phase of  immune suppression.
In immunosuppression, monocytes are characterized by 
a markedly reduced human leukocyte antigen-DR (HLA-
DR) expression, and a profound reduction of  their abil-
ity to produce proinflammatory cytokines, for example 
TNF-α[32,33]. Monocytes with low HLA-DR density show 
impaired antigen presentation capacity[34,35]. IL-10, the 
most potent anti-inflammatory cytokine, is responsible 
for the decreased monocyte HLA-DR expression[36]. IL-1 
receptor antagonist (IL-1ra) and IL-6 are also important 
anti-inflammatory cytokines. IL-1ra binds competitively to 
the IL-1 receptor and blocks IL-1 mediated responses[37]. 
Previously, IL-6 was regarded as a proinflammatory cy-
tokine. However, some years ago it was shown to act 
predominantly as an anti-inflammatory cytokine and, for 
example prevents synthesis of  IL-1β and TNF-α[38].
Altered cellular immune function in AP was first report-
ed by García-Sabrido et al[39] in 1989 when they showed a 
correlation between poor outcome and anergy to delayed-
type hypersensitivity testing. In addition to proinflamma-
tory mediators[40,41], the IL-10 plasma level has also been 
shown to be increased in severe AP[42] and predicts devel-
opment of  organ failure in the very early phase of  AP[43]. 
In AP patients, decreased monocyte HLA-DR expression 
























Figure 1  Two-phase hypothesis of development of multiorgan failure. MOF: 
Multiple organ failure; SIRS: Systemic inflammatory response syndrome; TNF: 
Tumor necrosis factor; IL: Interleukin; CARS: Compensatory anti-inflammatory 
response syndrome.
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is associated with development of  secondary infections[30]. 
Decreased monocyte HLA-DR expression has also been 
shown to predict development of  organ failure[44] and a 
fatal outcome[45]. In AP patients, high plasma levels of  
IL-10 and IL-6 correlate with decreased monocyte HLA-
DR expression[30]. IL-10 and IL-6 can be measured by a 
chemiluminescent immunoassay that could be available 
on a 24-h basis at the hospital emergency unit. Flow cyto-
metric measurement of  monocyte HLA-DR expression 
can be used as a routine clinical test and provides results 
within 30-60 min of  sampling. In addition to monocyte 
functions, there are changes also in lymphocyte count and 
proportion of  T-helper cells that can be measured by flow 
cytometry in severe AP[46].
DEVELOPMENT OF ORGAN FAILURE 
WORSENS PROGNOSIS
The classification of  AP severity is based on a consensus 
conference held in Atlanta in 1992[47]. According to the 
Atlanta classification, AP is classified as severe if  system-
ic and/or local complications (for example pancreatic 
necrosis, pseudocyst or abscess) are present. Otherwise, 
AP is classified as mild. Organ failure occurs in half  of  
patients with pancreatic necrosis[48].
The most common organ failure in severe AP is re-
spiratory failure. Also other organs may fail, e.g. renal, 
hepatic, cardiovascular, digestive, neurologic, coagula-
tion[17] or endocrine or immunologic systems[49]. Failure 
of  different organs has different effects on the prognosis 
of  the disease. Mortality rates in severe AP patients with 
respiratory, renal, and hepatic failure are 43%, 63%, and 
83%, respectively[50]. Lately, the Atlanta classification has 
been criticized because it does not separate organ failure 
from local complications[51]. Furthermore, the definition 
of  organ failure in the Atlanta classification is so wide 
that it includes many patients with a good prognosis. 
To overcome these shortcomings we have categorized 
the patients into 3 groups: patients who develop vital 
organ failure, patients who meet the Atlanta criteria for 
severe AP but do not develop organ failure, and patients 
who neither meet the Atlanta criteria nor develop or-
gan failure[41,43,44,52,53]. Indeed, in terms of  mortality and 
morbidity, the organ failure group is the critical one[8,9] 
regardless of  the presence or absence of  necrosis of  
the pancreas[54]. Organ failure often develops early in the 
course of  AP. As many as 37%-76% of  AP patients who 
will develop organ failure may have it already at admis-
sion[55,56] or develop it during the first 24 h[44]. Also a dif-
ference between transient (< 48 h) and persistent (> 48 h) 
organ failure has been noted[57,58]. Patients with transient 
organ failure have an uneventful recovery but persistent 
organ failure predicts death and local complications.
The mortality of  AP is biphasic. Half  of  the mortal-
ity takes place during the first week of  the disease and 
is related to severe multiorgan failure[6]. If  the patient 
survives the first week, he/she may get infectious com-
plications, such as sepsis, with worsening organ dysfunc-
tion. These events increase mortality during the second 
phase of  the disease[6]. Knowing the biphasic nature of  
the mortality is highly relevant to treatment and research 
of  novel treatment modalities in severe AP because 
the first peak occurs during on-going pro- and/or anti-
inflammatory responses whereas the second peak occurs 
at the phase of  immune suppression.
IMMUNE-MODULATION THERAPY
Current treatment of  AP remains unspecific and sup-
portive and is mainly targeted to aggressively prevent 
systemic complications by intensive care. Delayed admis-
sion to the intensive care unit results in a 4-fold excess 
in mortality[59]. Therefore, early identification of  patients 
who develop a severe AP with organ failure is essential 
for improved prognosis by earlier intervention with ap-
propriate resuscitation in specialized hospitals. 
At present, no specific medical therapy for AP exists. 
Several experimental studies and clinical trials have at-
tempted to discover medical treatment to inhibit the sys-
temic inflammatory reaction and, thus, the development 
of  multiple organ dysfunction. In a rat model of  AP, in 
contrast to expectations, anti-TNF antibody was found to 
be harmful[60]. However, when given prophylactically anti-
TNF antibodies decreased the severity of  AP[61]. In ex-
perimental AP, block of  the cytokine cascade at the level 
of  the IL-1 receptor with a specific antagonist (IL-1ra) 
decreased pancreatic damage[62]. Furthermore, anti-inflam-
matory therapy with an IL-10 agonist[63,64] and an anti-IL-8 
antibody[65] have shown beneficial effects. In addition, 
anti-adhesion therapy with anti-intercellular adhesion mol-
ecule-1 antibody ameliorates lung injury in mice with se-
vere AP[66]. Platelet-activating factor antagonist lexipafant 
was promising in the first clinical trials[67,68] but in the final 
trial the results were disappointing[55]. In the complex net-
work of  inflammatory responses, a combination therapy 
to inhibit several proinflammatory agents could be useful.
In clinical AP, patients are typically admitted to the 
emergency unit in a fairly late stage of  the disease when 
organ failure is about to develop or may already be pres-
ent. Then the patient has CARS or probably even immu-
nosuppression, initiation of  anti-inflammatory therapies 
could worsen the prognosis. Thus, the therapeutic window 
for anti-inflammatory therapies may be too narrow in 
clinical practice[55]. The problem of  early-occurring organ 
dysfunction in clinical trials is highlighted by the lexipafant 
study[55], in which 44% of  the patients met the criteria of  
organ failure prior to receiving the first dose of  the study 
drug, an inhibitor of  platelet activating factor, or placebo. 
In anergic septic patients immunostimulation with 
interferon-γ has proven to be beneficial[33]. In a clinical 
study of  septic patients, granulocyte macrophage stimu-
lating factor (GM-CSF) treatment was well tolerated and 
increased monocyte HLA-DR expression and TNF-α 
production capacity[69]. In severe AP, there is a defect in 
monocyte function. However, priming of  monocytes 
in vitro by interferon-γ and GM-CSF increased HLA-
DR expression and restored lipopolysaccharide-induced 
TNF-α secretion[70]. Yet, it is of  note, that immunosup-
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pression may be confined to the peripheral blood while 
the lungs and the other end organs may still be in the pro-
inflammatory stage. Therefore, immunostimulatory treat-
ment must be used cautiously and clinicians should have 
the means to monitor the patients’ immunoinflamma-
tory state. Currently, the best method is measurement of  
monocyte HLA expression by flow cytometry. It would be 
optimal to depress the pro-inflammatory reaction in the 
patients at risk of  excessive immune suppression so that 
inappropriate CARS would be prevented. An interesting 
question is whether the patients in whom a deep immune 
suppression develops, benefit from antimicrobial prophy-
laxis, along with immunostimulation. 
COAGULATION SYSTEM IS RELATED TO 
INFLAMMATION
In systemic inflammation, several proinflammatory cy-
tokines activate the coagulation process in the body[71] 
and activated endothelial cells seem to have an important 
contributing role in that process. Systemic coagulation 
activation results in thrombosis in small and middle-sized 
vessels in many organs, resulting in disseminated intra-
vascular coagulation (DIC), that leads to decreased blood 
circulation of  organs and organ failure. In DIC, consump-
tion of  platelets is increased resulting in thrombocytope-
nia which is a common sign of  severe AP[72]. The D-dimer 
level has been shown to be high in severe AP and serves 
as a marker of  DIC[73]. In experimental severe AP, it was 
demonstrated that microcirculatory disorders affecting 
capillary blood flow, capillary permeability and leukocyte 
endothelial interaction are present not only in the pancreas 
but also in the colon, liver, and lungs[28]. 
Protein C is a natural anticoagulant in blood and seems 
to have an essential role in the regulation of  the coagula-
tion cascade in inflammation. Protein C is activated by the 
thrombin-thrombomodulin complex at the endothelial 
surface[74]. Activated protein C (APC) inactivates factor 
Ⅴ and factor Ⅷ and inhibits thrombin generation. In 
experimental studies, APC has shown also to have anti-
inflammatory effects[75,76]. Septic patients have a decreased 
protein C level in blood and it correlates with poor prog-
nosis[77]. In meningococcemia patients with DIC, treat-
ment with APC has prevented development of  organ 
failure, and decreased mortality[78]. In patients with severe 
sepsis, treatment with APC was safe and resulted in de-
creased mortality[79,80]. In severe AP, protein C pathway de-
fects have been shown to be associated with development 
of  organ failure[81]. In a rat model of  severe AP, APC 
treatment reduced inflammation in the pancreas and lungs 
and improved survival[82]. These findings encouraged us to 
perform a placebo-controlled clinical trial of  APC in the 
treatment of  severe AP at the Helsinki University Central 
Hospital. 
FUTURE DIRECTIONS
Deeper understanding of  the cell biology and physiology 
of  AP is necessary to permit the design of  effective inter-
ventions concerning the inflammatory response process. 
Improved methods to accurately identify those patients with 
severe AP in need of  monitoring and treatment in inten-
sive care units are urgently needed. A means to monitor 
the state of  the immune response (monocyte HLA-DR 
expression) during hospitalization of  severe AP patients 
is important. Whether monitoring signaling pathways of  
circulating leukocytes, such as nuclear factor κB, signal 
transducers and activators of  transcription and members 
of  the mitogen activated protein kinase family helps us to 
find the patients at risk for secondary infections and, thus, 
late organ failure is at present under research[83]. Future 
treatment strategies will probably focus on combination 
therapy aimed at suppressing excessive activation of  the 
inflammatory response and preventing concomitantly 
overcompensating CARS and eventually immunosup-
pression. Because AP shares many features of  sepsis, an 
urgent question is whether APC provides a means to alle-
viate severe AP, as it does in patients with life-threatening 
sepsis. Finally, the analysis of  signaling patterns of  leuko-
cytes may reveal novel therapeutic targets in severe AP.
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